The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy
Open accessAbstract
OBJECTIVE: Treatment with heparin and low-dose aspirin improves fetal survival among women with antiphospholipid syndrome. Despite treatment, however, these pregnancies are frequently complicated by preeclampsia, fetal growth restriction, and placental insufficiency, often with the result of preterm birth. Small case series suggest that intravenous immune globulin may reduce the rates of these obstetric complications, but the efficacy of this treatment remains unproven. This pilot study was undertaken to determine the feasibility of a multicenter trial of intravenous immune globulin and to assess the impact on obstetric and neonatal outcomes among women with antiphospholipid syndrome of the addition of intravenous immune globulin to a heparin and low-dose aspirin regimen. STUDY DESIGN: This multicenter, randomized, double-blind pilot study compared treatment with heparin and low-dose aspirin plus intravenous immune globulin with heparin and low-dose aspirin plus placebo in a group of women who met strict criteria for antiphospholipid syndrome. All patients had lupus anticoagulant, medium to high levels of immunoglobulin G anticardiolipin antibodies, or both. Patients with a single live intrauterine fetus at </=12 weeks' gestation were randomly assigned to receive either intravenous immune globulin (1 g/kg body weight) or an identical-appearing placebo for 2 consecutive days each month until 36 weeks' gestation in addition to a heparin and low-dose aspirin regimen. Maternal characteristics, obstetric complications, and neonatal outcomes were compared with the Student t test and the Fisher exact test as appropriate. RESULTS: Sixteen women were enrolled during a 2-year period; 7 received intravenous immune globulin and 9 were given placebo. The groups were similar with respect to age, gravidity, number of previous pregnancy losses, and gestational age at the initiation of treatment. Obstetric outcomes were excellent in both groups, with all women being delivered of live-born infants after 32 weeks' gestation. The rates of antepartum complications such as preeclampsia, fetal growth restriction, and placental insufficiency (as manifested by fetal growth restriction or fetal distress) were similar between the 2 groups. Gestational age at delivery (intravenous immune globulin group, 34.6 +/- 1.1 weeks; placebo group, 36.7 +/- 2.1 weeks) and birth weights (intravenous immune globulin group, 2249.7 +/- 186.1 g; placebo group; 2604.4 +/- 868.9 g) were similar between the 2 groups. There were fewer cases of fetal growth restriction (intravenous immune globulin group, 0%; placebo group, 33%) and neonatal intensive care unit admission (intravenous immune globulin group, 20%; placebo group, 44%) among the infants in the intravenous immune globulin group than those in the placebo group, but these differences were not significant. CONCLUSION: A multicenter treatment trial of intravenous immune globulin is feasible. In this pilot study intravenous immune globulin did not improve obstetric or neonatal outcomes beyond those achieved with a heparin and low-dose aspirin regimen. Although not statistically significant, the findings of fewer cases of fetal growth restriction and neonatal intensive care unit admissions among the intravenous immune globulin-treated pregnancies may warrant expansion of the study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Treatment of Kawasaki Syndrome with Intravenous Gamma Globulin
Newburger, J. W., Takahashi, M., Burns, J. C., Beiser, A. S., Chung, K. J., Duffy, C. E., Glode, M. P., Mason, W. H., Reddy, V., Sanders, S. P., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198608073150601 · Cited by 1,419
Rai, R., Cohen, H., Dave, M., & Regan, L. (1997) · BMJ · doi:10.1136/bmj.314.7076.253 · Cited by 1,113
The “Primary” Antiphospholipid Syndrome: Major Clinical and Serological Features
ASHERSON, R. A., KHAMASHTA, M. A., ORDI-ROS, J., DERKSEN, R. H. W. M., MACHIN, S. J., BARQUINERO, J., OUTT, H. H., HARRIS, E. N., VILARDELL-TORRES, M., & HUGHES, G. R. V. (1989) · Medicine · doi:10.1097/00005792-198911000-00004 · Cited by 959
The "primary" antiphospholipid syndrome: major clinical and serological features.
Asherson, R. A., Khamashta, M. A., Ordi‐Ros, J., Derksen, R. H. W. M., Machin, S. J., Barquinero, J., OUTT, H. H., Harris, E. N., Vilardell, M., & Hughes, G. R. V. (1989) · PubMed · Cited by 892
Kutteh, W. H. (1996) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(96)70610-5 · Cited by 803
(1990) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(90)90653-o · Cited by 438
(1992) · PubMed · Cited by 434
(1996) · PubMed · Cited by 307
Antiphospholipid antibodies and fetal death
OSHIRO, B., SILVER, R., SCOTT, J., YU, H., & WAREBRANCH, D. (1996) · Obstetrics & Gynecology · doi:10.1016/0029-7844(95)00498-x · Cited by 230
Self-citationScott, J. R., Branch, D. W., Kochenour, N. K., & Ward, K. J. (1988) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(88)90411-5 · Cited by 136
Self-citation
Cited by
Levine, J. S., Branch, D. W., & Rauch, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmra002974 · Cited by 1,543
Self-citationIgG placental transfer in healthy and pathological pregnancies
Palmeira, P., Quinello, C., Silveira-Lessa, A. L., Zago, C. A., & Carneiro-Sampaio, M. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/985646 · Cited by 1,037
Ruiz-Irastorza, G., Crowther, M., Branch, W., & Khamashta, M. A. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60709-x · Cited by 831
Update on the use of immunoglobulin in human disease: A review of evidence
Perez, E. E., Orange, J. S., Bonilla, F., Chinen, J., Chinn, I. K., Dorsey, M., El-Gamal, Y., Harville, T. O., Hossny, E., Mazer, B., et al. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.09.023 · Cited by 666
Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant
Empson, M. B., Lassere, M., Craig, J. C., & Scott, J. R. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002859.pub2 · Cited by 486
Metadata
- Authors
- Branch, D. W., Peaceman, A. M., Druzin, M., Silver, R. K., El-Sayed, Y., Silver, R. M., Esplin, M. S., Spinnato, J., & Harger, J.
- Venue
- American Journal of Obstetrics and Gynecology
- Publisher
- Elsevier BV
- Published
- 2000-01
- Volume
- 182
- Issue
- 1
- Pages
- 122-127
- ISSN
- 0002-9378 (ISSN-L)
- OpenAlex
- W2044042100
- Cited by
- 318
- References
- 16
- FWCI
- 15.22
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. https://app.cochat.ai/papers/10.1016/s0002-9378(00)70500-x
- The paper
- Branch, D. W., Peaceman, A. M., Druzin, M., Silver, R. K., El-Sayed, Y., Silver, R. M., Esplin, M. S., Spinnato, J., & Harger, J. (2000). A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. American Journal of Obstetrics and Gynecology. https://doi.org/10.1016/s0002-9378(00)70500-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.